

OFFICE OF FISCAL ANALYSIS

Legislative Office Building, Room 5200
Hartford, CT 06106 ◊ (860) 240-0200
<http://www.cga.ct.gov/ofa>

sSB-895

AN ACT CONCERNING CHANGES TO VARIOUS PHARMACY STATUTES.

AMENDMENT

LCO No.: 7129

File Copy No.: 361

Senate Calendar No.: 223

OFA Fiscal Note

State Impact:

Agency Affected	Fund-Effect	FY 22 \$	FY 23 \$
Consumer Protection, Dept.	GF - Eliminates Cost in Bill	Up to \$200,000	None

Note: GF=General Fund

Municipal Impact: None

Explanation

The amendment changes the effective date of section 5 to July 1, 2022 and eliminates the cost in the underlying bill because the upgrade to the Prescription Drug Monitoring Program (PDMP) is anticipated to take place in FY 22. The PDMP is used by multiple states across the country and the first state to require opioid agonists for the treatment of a substance use disorder to be uploaded to the database will bear the cost of the upgrade¹.

The preceding Fiscal Impact statement is prepared for the benefit of the members of the General Assembly, solely for the purposes of information, summarization and explanation and does not represent the intent of the General Assembly or either chamber thereof for any purpose. In general, fiscal impacts are based upon a variety of informational sources, including the analyst's professional knowledge. Whenever applicable, agency data is consulted as part of the analysis, however final products do not necessarily reflect an assessment from any specific department.

¹ Multiple states are in the process of legislating this requirement and the PDMP is anticipated to be upgraded in FY 22.

Primary Analyst: ME
Contributing Analyst(s):

4/20/21
()